Clinical trial
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic…
NCT00443976 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00443976 |
|---|---|
| Title | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma |
| Official title | A Phase I Study of AT9283 Given As a 24 Hour Infusion on Days 1 and 8 Every Three Weeks in Patients With Advanced Incurable Malignancy |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | Astex Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | Aurora kinase inhibitor AT9283 |
| Enrollment | 35 |
| Start date | Jan 30, 2007 |
| Primary completion | Apr 9, 2010 |
| Completion | Jan 6, 2012 |
| First posted | Mar 7, 2007 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: